Quality of life in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus in CheckMate 025, a randomised, phase 3 clinical trial

BACKGROUND: In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma (aRCC) randomised to nivolumab had an overall survival (OS) benefit versus everolimus. We compared health-related quality of life (HRQoL) between treatment arms and explored the relationshi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Cella, David, Grünwald, Viktor, Nathan, Paul, Doan, Justin, Dastani, Homa, Taylor, Fiona, Bennett, Bryan, DeRosa, Michael, Berry, Scott, Broglio, Kristine, Berghorn, Elmer, Motzer, Robert J
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5521044/
https://ncbi.nlm.nih.gov/pubmed/27283863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30125-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi